Deep Dive Into Health Catalyst Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Health Catalyst (NASDAQ:HCAT) received mixed analyst ratings over the past three months, with 4 somewhat bullish and 2 indifferent ratings. The average 12-month price target is $10.83, down from $12.33, with a high estimate of $12.00 and a low of $8.00. Analysts from Evercore ISI Group, Piper Sandler, JP Morgan, Stifel, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Health Catalyst's financial performance shows a revenue growth rate of 7.93%, a net margin of -29.86%, an ROE of -5.71%, an ROA of -3.07%, and a debt-to-equity ratio of 0.65.
January 03, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst has a mix of somewhat bullish and indifferent ratings from analysts, with a lowered average price target of $10.83. Financial indicators show growth but also highlight profitability and asset utilization challenges.
The mixed analyst ratings and lowered price target suggest uncertainty, which could lead to a neutral short-term impact on HCAT's stock price. The financial performance indicates growth but also areas of concern, which may prevent a clear directional movement in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100